Lee JY, Boonyapipat S, Yuan G, Kim HS, et al. AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer. Gynecol Oncol 2025;198:25-32.
PMID: 40411966